Oct 2026· Frontiers in Pharmacology· Vol 17· 0 citations· 148 references
Medicine
TL;DR
It is concluded that the top-down pipeline-spanning network pharmacology to ML, docking, and MD-integrated with bottom-up feedback constitutes a closed-loop paradigm that accelerates lead identification while addressing emergent drug resistance.
Abstract
Tuberculosis (TB), driven by Mycobacterium tuberculosis (Mtb), remains a leading cause of mortality from infectious disease worldwide. The global dissemination of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains—coupled with protracted treatment regimens and the persistence of latent infection—has not only compromised first-line chemotherapies but also underscored the stagnation of conventional drug development pipelines. In this review, we systematically synthesize how multi-scale computational strategies are reshaping anti-TB drug discovery and explicitly delineate their hierarchical integration—a cohesive framework that, to our knowledge, has yet to be comprehensively mapped in the existing literature. We survey four interconnected computational layers: (i) systems and network pharmacology for macroscopic target and pathway prioritization; (ii) machine learning (ML) for mesoscopic virtual screening, resistance classification, and ADMET prediction; (iii) molecular docking for microscopic elucidation of ligand–target binding modes; and (iv) molecular dynamics (MD) simulations for atomic-level validation of binding poses and assessment of complex stability. Representative studies demonstrate that this workflow has pinpointed pivotal TB vulnerabilities (e.g., MmpL3, InhA, DprE1, ATP synthase, and FtsZ), enabled ML models to predict drug resistance from genomic data with high fidelity, and identified promising candidates such as vazabitide A (predicted binding affinity of −85.8 kcal/mol against Pks13) alongside repurposed agents (e.g., aldoxorubicin, quarfloxin). Critically, these computational predictions are reinforced by orthogonal experimental validation spanning in vitro enzymatic and phenotypic assays, in vivo infection models, clinical pharmacokinetic profiling, and multi-omics corroboration. We conclude that the top-down pipeline-spanning network pharmacology to ML, docking, and MD-integrated with bottom-up feedback constitutes a closed-loop paradigm that accelerates lead identification while addressing emergent drug resistance. Nevertheless, inherent limitations in predictive reliability and cross-layer error propagation necessitate rigorous downstream experimental validation. Looking forward, generative artificial intelligence, self-driving laboratories, and standardized cross-method benchmarking are poised to consolidate this multi-scale pipeline into a robust engine for next-generation anti-TB therapeutics.
This review critically evaluates current computational strategies for anti-TB drug screening, with particular emphasis on their performance under TB-specific biological and resistance constraints, and proposes a shift toward biologically grounded, regimen-aware, and systems-level frameworks.
Shan-Shan Hu, Xiao-Yu Li, Z. Batool et al.· Frontiers in Pharmacology· 0 citations
Computational phytochemistry represents a promising and cost-effective strategy for prioritizing phytochemicals against MDR/XDR-TB and offers a viable path for the revelation and development of unprecedented natural product-based anti-TB medications.
D. Sahu, B. Sahoo, Ashirbad Nanda et al.· Recent Advances in Anti-Infe...· 0 citations
This review critically evaluates AI-driven drug repurposing for MDR infections, addressing computational methodologies, data integration, experimental validation, translational bottlenecks, and regulatory considerations and outlines strategic pathways for integrating AI predictions with experimental and clinical workfl...
K. Amaihunwa, D. Egbule, A. O. Jewo et al.· Acta Microbiologica Hellenic...· 0 citations
This review underscores the critical role of bioinformatics in addressing the global burden of MDR-TB and highlights its transformative role in guiding next-generation anti-TB drug development.
Elizabeth Annie George, M. Senthilkumar, Kavitha Thirupugazh et al.· Beni-Suef University Journal...· 0 citations
A critically underexplored dimension, multi‐target drug discovery, is systematically examined, focusing on the design of dual‐pharmacophore inhibitors that simultaneously engage NDH‐2 and cytochrome bd oxidase, thereby raising the genetic barrier to resistance.
Said Moshawih, Anguraj Moulishankar, Chee-Yan Choo et al.· Chemical Biology and Drug De...· 0 citations
This study provides a thorough examination of bioinformatics research, highlighting how the integration of genomic, proteomic and metabolomic data into TB research has revolutionised the way TB is studied, particularly in understanding resistance mechanisms, identifying new therapeutic targets, and expediting the devel...
A. M. Hayawi· Modern Journal of Health and...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.